Market News Latest

All-Round Immune Checkpoint Research and Drug Development Service at Creative Biolabs

 Breaking News
  • No posts were found

All-Round Immune Checkpoint Research and Drug Development Service at Creative Biolabs

August 03
20:51 2022
Creative Biolabs offers high-quality immune checkpoint inhibitor development services and a full range of immune checkpoint-based solutions to accelerate immunotherapy projects.

New York, USA – August 3, 2022 – Recently, immune checkpoint inhibitors have emerged as a promising class of immunotherapy for cancer management. So far, several immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 have entered the market, and over 300 immune checkpoint inhibitors are in clinical trials, with a potential global market estimated at $30 billion approximately.

Based on a thorough understanding of signaling pathways and immune checkpoint molecules, Creative Biolabs has developed a comprehensive platform to afford immune checkpoint-associated antibodies, proteins, peptides, assays, small molecular drugs, etc.

Immune checkpoint-related services at Creative Biolabs:

• Immune checkpoint protein development

• Immune checkpoint antibody development

• Immune checkpoint targeted peptide development

• Immune checkpoint targeted small molecule drug development

• Biomarker development for immune checkpoint inhibitor

• Immune checkpoint assay

• Preclinical research on immune checkpoint drugs

Among these, with superior technical pipelines, immune checkpoint antibody development is a highlight service at Creative Biolabs. The service portfolio includes:

• Polyclonal antibody discovery and development

• Monoclonal antibody discovery and development

• Antibody fragment discovery and development

• Antibody characterization

• Antibody engineering and optimization

• Antibody production and manufacture

In addition, small molecules for immune checkpoint are also a compelling strategy as small molecule drugs are characterized by good spatial dispersion, drug properties, and pharmacokinetic properties. Current studies have revealed that a number of new checkpoint molecules have been verified for drug development and present anti-tumor activity in pre-clinical studies, such as 4-1BB, GITR, BTLA, B7-H4, TGF-ß, CD48, and BTNL2.

GITR and 4-1BB are costimulatory TNFR family members expressed on regulatory and effector T cells as well as the immune system of other cells.

4-1BB plays a critical role in sustaining effective T cell immune responses and generating immunological memory. In recent years, great progress has been made in elucidating the expression, function, and therapeutic potential of 4-1BB. GITR, also known as TNFRS18 or CD257, is an attractive target for immunotherapy, owing to its capacity to promote effector T cell functions and hamper regulatory T cell suppression. Creative Biolabs offers a wide range of services for drug development projects of diverse immune checkpoints like 4-1BB and GITR.

More information about immune checkpoint services can be found at

About Creative Biolabs

Creative Biolabs provides a full range of immune checkpoint antibody development services, immune checkpoint small molecule drug development services, and immune checkpoint assays. A series of high-quality immune checkpoint products are also available to support immune checkpoint research and drug discovery projects.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States